A new approach is changing how metastatic triple-negative breast cancer (mTNBC) is treated. Experts are now focusing on TROP2-targeted antibody-drug conjugates (ADCs) as a first-line therapy instead of traditional chemotherapy. Recent clinical studies suggest these targeted drugs can help patients live longer and delay disease progression. Three major Phase 3 trials reported in 2025 support […]
BTK inhibitors are moving from relapsed treatment to frontline therapy for Mantle Cell Lymphoma (MCL). A key question is whether patients who relapse after a fixed-duration BTK inhibitor can be successfully treated with the same drug again. In the past, failing a BTK inhibitor left patients with very limited options, so proving that “rechallenge” works
The Phase 1/2 OrigAMI-4 trial (Cohort 2) tested a first-line combination of subcutaneous amivantamab (Rybrevant Faspro) and pembrolizumab (Keytruda) in patients with HPV-unrelated, PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The therapy showed a 56% overall response rate, 74% clinical benefit rate, and tumor shrinkage in 82% of patients, with median
Endometrial cancer incidence and mortality are rising, creating a need for new therapies for advanced or recurrent disease, which has a poor 18.9% 5-year survival rate. Traditional efficacy endpoints often neglect patient quality of life (QoL), leading to the use of a post hoc analysis of the RUBY trial to assess quality-adjusted time without symptoms of
The Phase 3 PSMAddition study tested whether adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to standard treatment improves outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Patients received either standard therapy with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI), or the same treatment plus up to six cycles of Pluvicto.
Treatment with selinexor (Xpovio) for relapsed or refractory multiple myeloma is moving toward lower, more tolerable dosing. “Less is often more,” focusing on keeping patients on therapy longer rather than using high doses that cause more side effects. Instead of the older high-dose schedule of 80 mg twice weekly, doctors now favor a lower weekly
Selinexor Dosing Shift: Lower, Longer Treatment Improves Outcomes in Multiple Myeloma Read More »
Final results show that combining radium-223 (Xofigo) with enzalutamide (Xtandi) helps patients with bone-predominant metastatic castration-resistant prostate cancer live longer than treatment with enzalutamide alone. Patients who received the combination lived a median of 38.2 months, compared with 32.6 months for those on enzalutamide alone. The combination also delayed visible tumor growth on scans, extending
New data from the Phase 2 BRCAAway trial presented at the 2026 Genitourinary Cancers Symposium show that combining abiraterone, prednisone, and olaparib provides major benefits for patients with metastatic castration-resistant prostate cancer who carry BRCA1/2 or ATM mutations. The three-drug combination significantly outperformed either abiraterone or olaparib alone. Patients receiving the combination had a progression-free
Researchers have found a new way to help immunotherapy work better for patients with aggressive, recurrent high-grade astrocytoma, a serious type of brain cancer. One of the biggest challenges in treating brain tumors is the blood-brain barrier. This natural protective barrier prevents many drugs and immune cells from entering the brain, including treatments designed to
The TCOG T5217 trial compared two intensive chemotherapy regimens for advanced pancreatic cancer: mFOLFIRINOX, a modified global standard, and SLOG, an Asian-specific combination of S-1, leucovorin, oxaliplatin, and gemcitabine. Both treatments provided similar survival benefits, with median overall survival of 12.1 months for mFOLFIRINOX and 12.9 months for SLOG, and comparable progression-free survival and response